Marco Mura

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3429489/publications.pdf

Version: 2024-02-01

54	2,101	361045	233125
papers	citations	20	45
		h-index	g-index

57	57	57	2897
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis. Thorax, 2023, 78, 551-558.	2.7	8
2	Nutrition implications of intrinsic restrictive lung disease. Nutrition in Clinical Practice, 2022, 37, 239-255.	1.1	5
3	Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival. Respiratory Research, 2022, 23, .	1.4	3
4	Fat-Free Mass Index Controlled for Age and Sex and Malnutrition Are Predictors of Survival in Interstitial Lung Disease. Respiration, 2021, 100, 379-386.	1.2	7
5	TPMT and HLA-DQA1-HLA-DRB genetic profiling to guide the use of azathioprine in the treatment of interstitial lung disease: First experience. Pulmonary Pharmacology and Therapeutics, 2021, 66, 101988.	1.1	2
6	Use of nintedanib in interstitial lung disease other than idiopathic pulmonary fibrosis: much caution is warranted. Pulmonary Pharmacology and Therapeutics, 2021, 66, 101987.	1.1	6
7	Exercise capacity and its relationship with body composition and nutrition status in patients with interstitial lung disease. Nutrition in Clinical Practice, 2021, 36, 891-898.	1.1	4
8	Tobacco Workerâ€™s Lung: A Neglected Subtype of Hypersensitivity Pneumonitis. Lung, 2021, 199, 13-19.	1.4	5
9	Exercise Testing in Idiopathic Pulmonary Fibrosis: Expanding Our Options. Respiration, 2021, 100, 568-570.	1.2	1
10	Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial. BMC Pulmonary Medicine, 2021, 21, 396.	0.8	0
11	The CALIPER-Revised Version of the Composite Physiologic Index is a Better Predictor of Survival in IPF than the Original Version. Lung, 2020, 198, 169-172.	1.4	7
12	Invasive pulmonary aspergillosis in an immunocompetent, heavy smoker of marijuana with emphysema and chronic obstructive pulmonary disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, , 1-4.	0.2	2
13	Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters?. Respiratory Research, 2020, 21, 119.	1.4	15
14	Bronchiolitis obliterans syndrome as manifestation of lung GVHD: Not the only one. Respirology, 2019, 24, 702-702.	1.3	2
15	Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension. Respirology, 2019, 24, 1104-1110.	1.3	76
16	Implementing an interstitial lung disease clinic improves survival without increasing health care resource utilization. Pulmonary Pharmacology and Therapeutics, 2019, 56, 94-99.	1.1	7
17	Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity. Lung, 2018, 196, 707-713.	1.4	9
18	Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias. Respiration, 2018, 96, 543-551.	1.2	7

#	Article	IF	Citations
19	Comprehensive gene expression profiling identifies distinct and overlapping transcriptional profiles in non-specific interstitial pneumonia and idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 153.	1.4	66
20	Interstitial Lung Disease, Body Mass Index, Energy Expenditure and Malnutritionâ€"a Review. Current Pulmonology Reports, 2017, 6, 70-74.	0.5	5
21	Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment. Respiratory Medicine, 2017, 125, 65-71.	1.3	13
22	Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?. Lung, 2017, 195, 101-105.	1.4	8
23	A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease. Respirology, 2017, 22, 501-507.	1.3	35
24	A 53-year-old man with dyspnoea, respiratory failure, consistent with infliximab-induced acute interstitial pneumonitis after an accelerated induction dosing schedule. BMJ Case Reports, 2017, 2017, bcr-2017-219956.	0.2	6
25	Successful Treatment of Fibrosing Organising Pneumonia Causing Respiratory Failure with Mycophenolic Acid. Respiration, 2016, 92, 279-282.	1.2	7
26	Pulmonary Artery Abnormalities in Ex-smokers with and without Airflow Obstruction. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 224-234.	0.7	7
27	Early Decline in Six-Minute Walk Distance from the Time of Diagnosis Predicts Clinical Worsening in Pulmonary Arterial Hypertension. Respiration, 2015, 89, 365-373.	1.2	9
28	Depletion of Bone Marrow CCSP-Expressing Cells Delays Airway Regeneration. Molecular Therapy, 2015, 23, 561-569.	3.7	15
29	Metabolomic Heterogeneity of Pulmonary Arterial Hypertension. PLoS ONE, 2014, 9, e88727.	1.1	111
30	6-minute walk distance as a predictor of outcome in idiopathic pulmonary fibrosis. European Respiratory Journal, 2014, 43, 1822-1823.	3.1	1
31	Multi-dimensional indices to stage idiopathic pulmonary fibrosis: a systematic review. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2014, 31, 8-18.	0.2	9
32	Bone Marrow Cells Expressing Clara Cell Secretory Protein Increase Epithelial Repair After Ablation of Pulmonary Clara Cells. Molecular Therapy, 2013, 21, 1251-1258.	3.7	15
33	Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. European Respiratory Journal, 2012, 40, 101-109.	3.1	179
34	Gene Expression Profiling in the Lungs of Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis. Chest, 2012, 141, 661-673.	0.4	49
35	Src tyrosine kinase inhibition prevents pulmonary ischemiaâ€"reperfusion-induced acute lung injury. Intensive Care Medicine, 2012, 38, 894-905.	3.9	49
36	PTX3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation. Intensive Care Medicine, 2010, 36, 356-364.	3.9	40

#	Article	IF	Citations
37	Functions of Type II Pneumocyte-Derived Vascular Endothelial Growth Factor in Alveolar Structure, Acute Inflammation, and Vascular Permeability. American Journal of Pathology, 2010, 176, 1725-1734.	1.9	42
38	Metabolic syndrome and risk of pulmonary involvement. Respiratory Medicine, 2010, 104, 47-51.	1.3	18
39	HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. Respiratory Medicine, 2008, 102, 1753-1761.	1.3	54
40	Acute lung injury and cell death: how many ways can cells die?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L632-L641.	1.3	197
41	Review: New perspectives in the treatment of idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2008, 2, 75-93.	1.0	25
42	Anti-Human Tissue Factor Antibody Ameliorated Intestinal Ischemia Reperfusion-Induced Acute Lung Injury in Human Tissue Factor Knock-In Mice. PLoS ONE, 2008, 3, e1527.	1.1	21
43	High-volume ventilation induces pentraxin 3 expression in multiple acute lung injury models in rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L144-L153.	1.3	42
44	INTESTINAL ISCHEMIA-REPERFUSION-INDUCED ACUTE LUNG INJURY AND ONCOTIC CELL DEATH IN MULTIPLE ORGANS. Shock, 2007, 28, 227-238.	1.0	9
45	ANGIOTENSIN-CONVERTING ENZYME INHIBITOR CAPTOPRIL PREVENTS OLEIC ACID-INDUCED SEVERE ACUTE LUNG INJURY IN RATS. Shock, 2007, 28, 106-111.	1.0	66
46	The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival. Critical Care, 2006, 10, R130.	2.5	65
47	Functional Predictors of Exertional Dyspnea, 6-min Walking Distance and HRCT Fibrosis Score in Idiopathic Pulmonary Fibrosis. Respiration, 2006, 73, 495-502.	1.2	44
48	The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. Respiratory Care, 2006, 51, 257-65.	0.8	70
49	Inflammatory activity is still present in the advanced stages of idiopathic pulmonary fibrosis. Respirology, 2005, 10, 609-614.	1.3	19
50	Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. Journal of Thoracic and Cardiovascular Surgery, 2005, 129, 1144-1152.	0.4	290
51	TNFÎ±-Induced Long Pentraxin PTX3 Expression in Human Lung Epithelial Cells via JNK. Journal of Immunology, 2005, 175, 8303-8311.	0.4	166
52	Bullous emphysema versus diffuse emphysema: a functional and radiologic comparison. Respiratory Medicine, 2005, 99, 171-178.	1.3	11
53	Does Technetium-99m Diethylenetriaminepentaacetate Clearance Predict the Clinical Course of Idiopathic Pulmonary Fibrosis?. Canadian Respiratory Journal, 2004, 11, 477-479.	0.8	7
54	Vascular endothelial growth factor and related molecules in acute lung injury. Journal of Applied Physiology, 2004, 97, 1605-1617.	1.2	165